227 related articles for article (PubMed ID: 29766327)
41. Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway.
Liu ZL; Jin BJ; Cheng CG; Zhang FX; Wang SW; Wang Y; Wu B
Eur Rev Med Pharmacol Sci; 2017 Dec; 21(23):5370-5377. PubMed ID: 29243778
[TBL] [Abstract][Full Text] [Related]
42. MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1.
Ma Y; Li X; Cheng S; Wei W; Li Y
Mol Med Rep; 2015 Jan; 11(1):625-32. PubMed ID: 25339370
[TBL] [Abstract][Full Text] [Related]
43. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression.
Sui C; Meng F; Li Y; Jiang Y
J Transl Med; 2015 Apr; 13():132. PubMed ID: 25927928
[TBL] [Abstract][Full Text] [Related]
44. Bortezomib- and carfilzomib-resistant myeloma cells show increased activity of all three arms of the unfolded protein response.
Kubicki T; Bednarek K; Kostrzewska-Poczekaj M; Luczak M; Lewandowski K; Gil L; Jarmuz-Szymczak M; Dytfeld D
Am J Cancer Res; 2022; 12(7):3280-3293. PubMed ID: 35968359
[TBL] [Abstract][Full Text] [Related]
45. Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phena nthridini um hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines.
Kanzawa F; Nishio K; Ishida T; Fukuda M; Kurokawa H; Fukumoto H; Nomoto Y; Fukuoka K; Bojanowski K; Saijo N
Br J Cancer; 1997; 76(5):571-81. PubMed ID: 9303354
[TBL] [Abstract][Full Text] [Related]
46. MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1.
Pei K; Zhu JJ; Wang CE; Xie QL; Guo JY
Eur Rev Med Pharmacol Sci; 2016 Nov; 20(22):4697-4704. PubMed ID: 27906433
[TBL] [Abstract][Full Text] [Related]
47. Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib.
Barbagallo I; Giallongo C; Volti GL; Distefano A; Camiolo G; Raffaele M; Salerno L; Pittalà V; Sorrenti V; Avola R; Di Rosa M; Vanella L; Di Raimondo F; Tibullo D
Mol Neurobiol; 2019 Feb; 56(2):1451-1460. PubMed ID: 29948946
[TBL] [Abstract][Full Text] [Related]
48. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.
Chen P; Li J; Chen YC; Qian H; Chen YJ; Su JY; Wu M; Lan T
Cell Oncol (Dordr); 2016 Dec; 39(6):511-522. PubMed ID: 27473273
[TBL] [Abstract][Full Text] [Related]
49. Silence of fibronectin 1 increases cisplatin sensitivity of non-small cell lung cancer cell line.
Gao W; Liu Y; Qin R; Liu D; Feng Q
Biochem Biophys Res Commun; 2016 Jul; 476(1):35-41. PubMed ID: 27207836
[TBL] [Abstract][Full Text] [Related]
50. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.
Allegra A; Speciale A; Molonia MS; Guglielmo L; Musolino C; Ferlazzo G; Costa G; Saija A; Cimino F
Toxicol In Vitro; 2018 Mar; 47():186-194. PubMed ID: 29223572
[TBL] [Abstract][Full Text] [Related]
51. Characterization of three B-cell lymphoma cell lines from chemotherapy resistant patients with respect to in vitro sensitivity to 21 antitumor agents, ABC-transporter expression and cellular redox status.
Bracht K; Kiefer T; Dölken G; Bednarski PJ
J Cancer Res Clin Oncol; 2007 Dec; 133(12):957-67. PubMed ID: 17562080
[TBL] [Abstract][Full Text] [Related]
52. Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines.
Tatidis L; Masquelier M; Vitols S
Biochem Pharmacol; 2002 Jun; 63(12):2169-80. PubMed ID: 12110376
[TBL] [Abstract][Full Text] [Related]
53. Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
Xiao J; Egger ME; McMasters KM; Hao H
BMC Cancer; 2018 Jun; 18(1):675. PubMed ID: 29929490
[TBL] [Abstract][Full Text] [Related]
54. Carfilzomib reverses pulmonary arterial hypertension.
Wang X; Ibrahim YF; Das D; Zungu-Edmondson M; Shults NV; Suzuki YJ
Cardiovasc Res; 2016 May; 110(2):188-99. PubMed ID: 26952044
[TBL] [Abstract][Full Text] [Related]
55. L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines.
Chiu LY; Ko JL; Lee YJ; Yang TY; Tee YT; Sheu GT
Toxicol Lett; 2010 Feb; 192(3):408-18. PubMed ID: 19944135
[TBL] [Abstract][Full Text] [Related]
56. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer.
Yu S; Qin X; Chen T; Zhou L; Xu X; Feng J
Anticancer Drugs; 2017 Sep; 28(8):852-860. PubMed ID: 28723865
[TBL] [Abstract][Full Text] [Related]
57. Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy.
Ren JH; He WS; Nong L; Zhu QY; Hu K; Zhang RG; Huang LL; Zhu F; Wu G
Cancer Biother Radiopharm; 2010 Feb; 25(1):75-80. PubMed ID: 20187799
[TBL] [Abstract][Full Text] [Related]
58. Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
Lee MJ; Bhattarai D; Yoo J; Miller Z; Park JE; Lee S; Lee W; Driscoll JJ; Kim KB
J Med Chem; 2019 May; 62(9):4444-4455. PubMed ID: 30964987
[TBL] [Abstract][Full Text] [Related]
59. ABCG2 regulates the pattern of self-renewing divisions in cisplatin-resistant non-small cell lung cancer cell lines.
Tang Y; Hou J; Li G; Song Z; Li X; Yang C; Liu W; Hu Y; Xu Y
Oncol Rep; 2014 Nov; 32(5):2168-74. PubMed ID: 25200103
[TBL] [Abstract][Full Text] [Related]
60. Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
Zhang D; Ochi N; Takigawa N; Tanimoto Y; Chen Y; Ichihara E; Hotta K; Tabata M; Tanimoto M; Kiura K
Cancer Lett; 2011 Oct; 309(2):228-35. PubMed ID: 21742432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]